153 related articles for article (PubMed ID: 28338356)
1. The accessory gene regulator-1 as a therapeutic target for C. difficile infections.
Darkoh C; DuPont HL
Expert Opin Ther Targets; 2017 May; 21(5):451-453. PubMed ID: 28338356
[No Abstract] [Full Text] [Related]
2. Accessory Gene Regulator-1 Locus Is Essential for Virulence and Pathogenesis of Clostridium difficile.
Darkoh C; Odo C; DuPont HL
mBio; 2016 Aug; 7(4):. PubMed ID: 27531912
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory Effect of Epigallocatechin Gallate on the Virulence of Clostridium difficile PCR Ribotype 027.
Yun B; Oh S; Song M; Hong YS; Park S; Park DJ; Griffiths MW; Oh S
J Food Sci; 2015 Dec; 80(12):M2925-31. PubMed ID: 26556797
[TBL] [Abstract][Full Text] [Related]
4. Nonantimicrobial drug targets for Clostridium difficile infections.
Darkoh C; Deaton M; DuPont HL
Future Microbiol; 2017 Sep; 12(11):975-985. PubMed ID: 28759258
[TBL] [Abstract][Full Text] [Related]
5. Acyldepsipeptide antibiotics as a potential therapeutic agent against Clostridium difficile recurrent infections.
Gil F; Paredes-Sabja D
Future Microbiol; 2016 Sep; 11():1179-89. PubMed ID: 27546386
[TBL] [Abstract][Full Text] [Related]
6. Clostridium difficile infection: New insights into therapeutic options.
Kachrimanidou M; Sarmourli T; Skoura L; Metallidis S; Malisiovas N
Crit Rev Microbiol; 2016 Sep; 42(5):773-9. PubMed ID: 25955884
[TBL] [Abstract][Full Text] [Related]
7. Is pediatric Clostridium difficile infection associated with prior antibiotic exposure?
Kociolek LK; Gerding DN
Future Microbiol; 2014; 9(7):825-8. PubMed ID: 25156370
[No Abstract] [Full Text] [Related]
8. Activity of RBx 11760, a novel biaryl oxazolidinone, against Clostridium difficile.
Mathur T; Kumar M; Barman TK; Kumar GR; Kalia V; Singhal S; Raj VS; Upadhyay DJ; Das B; Bhatnagar PK
J Antimicrob Chemother; 2011 May; 66(5):1087-95. PubMed ID: 21393140
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization and antimicrobial susceptibilities of Clostridium difficile clinical isolates from Victoria, Australia.
Mackin KE; Elliott B; Kotsanas D; Howden BP; Carter GP; Korman TM; Riley TV; Rood JI; Jenkin GA; Lyras D
Anaerobe; 2015 Aug; 34():80-3. PubMed ID: 25944720
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of antimicrobial resistance and association with toxin genes in Clostridium difficile in commercial swine.
Thakur S; Putnam M; Fry PR; Abley M; Gebreyes WA
Am J Vet Res; 2010 Oct; 71(10):1189-94. PubMed ID: 20919905
[TBL] [Abstract][Full Text] [Related]
11. Is tigecycline a suitable option for Clostridium difficile infection? Evidence from the literature.
Di Bella S; Nisii C; Petrosillo N
Int J Antimicrob Agents; 2015 Jul; 46(1):8-12. PubMed ID: 25982915
[TBL] [Abstract][Full Text] [Related]
12. Clostridium difficile. A super serious bug.
Mayo Clin Health Lett; 2012 Apr; 30(4):6. PubMed ID: 22649818
[No Abstract] [Full Text] [Related]
13. Clostridium-DT(DB): a comprehensive database for potential drug targets of Clostridium difficile.
Jadhav A; Ezhilarasan V; Prakash Sharma O; Pan A
Comput Biol Med; 2013 May; 43(4):362-7. PubMed ID: 23415847
[TBL] [Abstract][Full Text] [Related]
14. [Refractory Clostridium difficile infection. Untraditional treatment of antibiotic-induced colitis].
Fløtterød O; Hopen G
Tidsskr Nor Laegeforen; 1991 Apr; 111(11):1364-5. PubMed ID: 2042156
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of fidaxomicin for Clostridium difficile treatment.
Simon MS
Clin Infect Dis; 2014 Feb; 58(4):603. PubMed ID: 24300043
[No Abstract] [Full Text] [Related]
16. Trial watch: Phase III success for novel Clostridium difficile antibiotic.
Nat Rev Drug Discov; 2010 Apr; 9(4):260. PubMed ID: 20357795
[No Abstract] [Full Text] [Related]
17. Novel therapeutic strategies for Clostridium difficile infections.
Ünal CM; Steinert M
Expert Opin Ther Targets; 2016; 20(3):269-85. PubMed ID: 26565670
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection.
Gerding DN; Hecht DW; Louie T; Nord CE; Talbot GH; Cornely OA; Buitrago M; Best E; Sambol S; Osmolski JR; Kracker H; Locher HH; Charef P; Wilcox M
J Antimicrob Chemother; 2016 Jan; 71(1):213-9. PubMed ID: 26433782
[TBL] [Abstract][Full Text] [Related]
19. Big browser is watching you.
Häfner SJ
Microbes Infect; 2018 May; 20(5):271-274. PubMed ID: 29684572
[No Abstract] [Full Text] [Related]
20. Susceptibility of Clostridium difficile Isolates of Varying Antimicrobial Resistance Phenotypes to SMT19969 and 11 Comparators.
Freeman J; Vernon J; Vickers R; Wilcox MH
Antimicrob Agents Chemother; 2016 Jan; 60(1):689-92. PubMed ID: 26552981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
